NORTH READING, Mass. — Aphios Corporation said the U.S. Patent and Trademark Office has issued a notice of allowance for a divisional patent application covering novel Bryoid compounds with potential therapeutic applications in neurodegenerative diseases, HIV latency, cancer and other amyloid-mediated disorders.
The patent application, titled “Bryoid Compositions, Methods of Making and Use Thereof,” covers a novel Bryoid composition known as B14B, including methods for isolation, purification and manufacturing.
Aphios said the USPTO determined that the claimed Bryoid composition demonstrated novelty and non-obviousness over prior bryostatin-related art.
The application is part of Aphios’ broader Bryoid intellectual property portfolio, which is derived from marine bryozoan natural products and advanced purification technologies. The company said the invention was developed with support from the National Institute on Aging and the National Institutes of Health.
Bryoids are structurally related to bryostatins, a class of complex macrocyclic compounds known to modulate protein kinase C pathways involved in neurodegeneration, viral latency and oncology.
According to the patent specification, several novel Bryoid compositions demonstrated biological activity comparable to or greater than Bryostatin-1 in stimulating alpha-secretase activity and protein kinase C signaling pathways associated with Alzheimer’s disease and other central nervous system disorders.
The application also describes multiple proprietary Bryoid analogs with molecular weights distinct from known Bryostatins 1 through 20. Experimental data included in the application showed enhanced alpha-secretase activity and protein kinase C modulation in SHSY-5Y neuroblastoma cells.
“Our Bryoid platform represents a significant advancement in the discovery and development of novel marine-derived therapeutics,” said Dr. Trevor P. Castor, Founder and CEO of Aphios Corporation. “This Notice of Allowance further validates the novelty of our Bryoid technology and strengthens our intellectual property estate in neurodegenerative disease therapeutics, HIV latency reversal strategies, and oncology applications.”
Aphios said its Bryoid platform combines proprietary extraction, purification and characterization technologies, including its SuperFluids processing platform, to isolate highly pure Bryoid compounds from Bugula neritina and related marine sources.
The company said the compounds may serve as next-generation therapeutics for Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, HIV-1 latency reversal and other serious disorders with significant unmet need.
The notice of allowance follows previously issued Aphios patents covering Bryoid compositions and expands the company’s portfolio of more than 85 issued and pending U.S. and international patents.
